Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis

Max Mimpen1, Linda Rolf1, Geert Poelmans2, Jody van den Ouweland3, Raymond Huppers1,4, Jan Damoiseaux5, Joost Smolders6,7∗

1 School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands, 2 Department of Human Genetics, Radboud University Medical Center, Nijmegen, Netherlands, 3 Department of Clinical Chemistry, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands, 4 Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, Netherlands, 5 Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, 6 MS Center ErasMS, Departments of Neurology and Immunology, Erasmus University Medical Center, Rotterdam, Netherlands, 7 Department of Neuroimmunology, Netherlands Institute for Neuroscience, Amsterdam, Netherlands

∗j.j.f.m.smolders@erasmusmc.nl

Abstract

Introduction
A poor 25-hydroxyvitamin D (25(OH)D) status is a much replicated risk factor for developing multiple sclerosis (MS), and several vitamin D-associated single nucleotide polymorphisms (SNPs) have been associated with a higher risk of MS. However, studies on the benefit of vitamin D supplementation in MS show inconclusive results. Here, we explore whether vitamin D-associated SNPs and MS risk alleles confound serological response to vitamin D supplementation.

Methods
34 participants from the SOLARIUM study consented to genotyping, of which 26 had vitamin D data available. The SOLARIUM study randomised relapsing-remitting MS patients to placebo or 14,000 IU vitamin D3 for 48 weeks. Participants were categorised as either ‘carriers’ or ‘non-carriers’ of the risk allele for 4 SNPs: two related to D binding protein (DBP) and associated with lower 25(OH)D levels (rs4588 and rs7041), and two related to vitamin D metabolism enzymes CYP27B1 and CYP24A1 and associated with a higher risk of MS (rs12368653; rs2248359, respectively). 25(OH)D levels were determined at baseline and after 48 weeks.

Results
The DBP-related SNPs showed no difference in 25(OH)D status at baseline, but carriers of the rs7041 risk allele showed lower 25(OH)D-levels compared to non-carriers after 48 weeks of supplementation (median 224.2 vs. 332.0 nmol/L, p = 0.013). For CYP related
SNPs, neither showed a difference at baseline, but carriers of the rs12368653 risk allele showed higher 25(OH)D-levels compared to non-carriers after 48 weeks of supplementation (median 304.1 vs. 152.0 nmol/L, p = 0.014).

**Discussion**

Vitamin D-related SNPs affect the serological response to high-dose vitamin D supplementation. The effects on more common doses of vitamin D, as well as the clinical consequence of this altered response, need to be investigated further.

1. Introduction

Although the exact aetiology of multiple sclerosis (MS) remains unknown, many factors, both genetic and environmental, have been identified as contributors to the disease. Low levels of circulating 25-hydroxyvitamin D (25(OH)D) are a much replicated risk factor for both the pathogenesis [1-3] and disease course of MS [4-6]. Genome wide association studies show that some MS risk alleles are situated in or near genes coding for enzymes related to vitamin D metabolism [7]. Indeed, MS patients tend to have a genetic background that is associated with lower 25(OH)D levels [8], and low 25(OH)D levels are in turn associated with a higher risk of MS disease activity. [4-6]. Many studies have investigated the supplementation of 25(OH)D in order to correct this lower level of 25(OH)D. However, these studies show mixed results, with some showing no clinical benefit [9, 10], while others report a protective effect of high-dose vitamin D supplementation [11-14].

A study by Bhargava et al. showed an attenuated elevation of circulating 25(OH)D levels after vitamin D supplementation in MS patients, compared to healthy controls [15]. Recently, Graves et al. reported that vitamin D related single nucleotide polymorphisms (SNPs) associated with lower 25(OH)D levels, associate with an increased relapse risk in paediatric MS patients [16]. However, it remains unclear whether these genetic variations are confounding factors in clinical supplementation studies. In this respect, elucidating the effects of vitamin D-related genetic background on supplementation studies is important for the interpretation of the results from these studies. Therefore, we have evaluated the influence of several vitamin D metabolism-related polymorphisms on the serological response to high dose vitamin D supplementation, in a cohort of interferon-beta treated relapsing-remitting MS patients from the SOLARIUM study [17].

2. Methods and materials

2.1 Patients

This study is a post-hoc extended analysis of the SOLARIUM study, which was a sub-study of the SOLAR study. The SOLAR study evaluated disease activity in interferon beta-treated RRMS patients using high dose vitamin D₃ supplements compared to placebo. The SOLARIUM study investigated the effect of high dose vitamin D₃ supplementations on the immune system composition. After randomisation, participants received either interferon-beta and a placebo or interferon-beta and vitamin D₃ supplements (cholecalciferol, Vigantol® Oil, Merck KGaA, Darmstadt, Germany) of 7,000 IU daily for 4 weeks, followed by 14,000 IU daily up to week 48. In- and exclusion criteria for the SOLAR and SOLARIUM studies are described elsewhere [13, 17]. Originally, genetic markers regarding vitamin D status were planned to be
gathered of all participants in the SOLAR study [18]. Ultimately, however, this analysis was not performed. Therefore, we acquired ethical approval to approach Dutch participants of SOLAR to acquire written informed consent for genetic analysis (Ethical Committee METC-Z, 11-T-03; Heerlen, the Netherlands). This resulted in 34 of 53 participants of the SOLARSTUDY to provide consent for genetic analysis.

2.2 Vitamin D measurements

Plasma samples were collected at baseline and week 48 and stored at −80°C. Plasma levels of 25(OH)D were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) following earlier published procedures [19, 20]. Coefficients of variation (CV) were 7.4% at 36 nmol/L, 4.0% at 88 nmol/L, and 3.1% at 124 nmol/L, respectively. Lower limit of quantification was 1 nmol/L [21]. From the SOLAR dataset, serum 25(OH)D and 1,25(OH)D levels were available as determined using the DiaSorin immunoassay method, with an upper limit of 250 nmol/L [13].

Of all participant providing consent for genetic analyses, N = 20/34 were allocated to the high-dose vitamin D₃ supplementation arm (Fig 1). Of these 20 participants, three had no biomaterial available for 25(OH)D analysis by the LC-MS/MS method. For these three participants, 25(OH)D levels were available as determined with the immunoassay as used in the SOLAR trial [13]. Since these 3 individuals had week 48 levels of 25(OH)D below the assay

---

**Fig 1. Flowchart depicting availability of data for our analyses.** LC-MS/MS: Liquid chromatography-tandem mass spectrometry.

https://doi.org/10.1371/journal.pone.0261097.g001
upper detection limit (<250 nmol/L), and we earlier reported a good correlation between the immunoassay and LC-MS/MS within this range (R = 0.917, [21]), we converted for these individuals their 25(OH)D status using a linear model.

2.3 Defining SNPs of interest
We selected for our study two SNPs that are missense variants in the gene encoding vitamin D-binding protein (DBP, or Group Component) (rs4588 and rs7041), as well as one SNP near the CYP27B1 gene (rs12368653) and one SNP near the CYP24A1 gene (rs2248359), which are all related to vitamin D metabolism. SNPs rs12368653 and rs2248359 have been identified as MS risk-alleles in a recent large GWAS [7]. The DBP-associated SNPs rs4588 and rs7041 have been reported as top-hits in several GWAS studies on determinants of 25(OH)D status in healthy and diseased cohorts [22–24]. Although not all GWAS studies support these specific DBP SNPs, DBP has been identified in all GWAS as a locus influencing 25(OH)D levels [25, 26]. Since the rs7041 and rs4588 SNPs were also associated with response to low-dose vitamin D supplementation in non-MS cohorts [27–29], we included these SNPs in our analysis. We genotyped rs2248359, the others were imputed using the RICOPILI pipeline and the Michigan server (HRC-reference panel). Genotyping was performed using extracted DNA from buffy coats. This DNA was analysed on the Infinium PsychArray-24v1.3_A1 BeadChip (Infinium array technology) and the polymorphisms of interest were defined through standard protocols.

2.4 Statistical analysis
SPSS software (IBM SPSS, version 25.0. Chicago, IL) was used to evaluate the differences in vitamin D status between carriers of risk alleles versus non-carriers. Normality of data was assessed by visual inspection of normality plots, as well as the Shapiro-Wilk test. To compare baseline characteristics, Mann-Whitney U tests were used to compare continuous data, while chi square tests were used to compare dichotomous data. Because of sample sizes, a Mann-Whitney U test was used to compare 25(OH)D levels between carriers and non-carriers. Previously, we have shown BMI to be a confounder in vitamin D levels in MS patients. Therefore, we have marked all patients with a BMI ≥25kg/m² in our analyses. A p-value of <0.05 was considered statistically significant.

3. Results
3.1 Baseline characteristics
In the original SOLARIUM trial, 53 participants completed the 48 week follow-up. Of these participants, 34 participants consented to genetic analysis; 14 participants received placebo and 20 participants received high-dose vitamin D₃ supplementation. Regarding vitamin D assays, 26 of the 34 participants had material available for the LC-MS/MS method at baseline and at week 48. Of these 26 participants, 9 received placebo and 17 received high-dose vitamin D₃ supplementation. For the 3 remaining participants that received high-dose vitamin D₃ supplementation, immunoassay data were available and these were converted as described in section 2.2 (Fig 2). After a 48 week follow-up, 6 of the 26 participants showed signs of MRI activity, 19 showed no signs of MRI activity and 1 was unavailable for MRI analysis. For all baseline characteristics, as well as treatment arm and MRI outcome, no statistically significant difference was observed between the SOLARIUM group and this subcohort (Table 1).
Fig 2. Differences in 25(OH)D levels between carriers and non-carriers of DBP related risk alleles. 25(OH)D levels at baseline (N = 26) (A) and after 48 weeks of supplementation (N = 20) (B), compared between non-carriers (left group) and carriers (right group) of the rs4588 and rs7041 risk alleles. P-value shown is calculated using a Mann-Whitney U test. Triangles indicate calculated data, derived from immunoassay values to replace missing values from the LC-MS/MS method.

Table 1. Baseline characteristics of the studied participants.

|                                      | Participants with available genetic material (N = 26) | Total SOLARIUM population (N = 53) | p-value |
|--------------------------------------|------------------------------------------------------|-----------------------------------|---------|
| **Sex (N[%])**                       |                                                      |                                   | 0.777   |
| Female                               | 18 [69]                                              | 35 [66]                           |         |
| Male                                 | 8 [31]                                               | 18 [34]                           |         |
| **Age (years: median [interquartile range])** | 39.9 [32.6–45.1]                                     | 36.2 [31.4–43.9]                  | 0.591   |
| **Body Mass Index (BMI) (N[ %])**    |                                                      |                                   | 0.802   |
| < 25 kg/m²                           | 11 [42]                                              | 24 [45]                           |         |
| ≥ 25 kg/m²                           | 15 [58]                                              | 29 [55]                           |         |
| **Disease duration (months: median [interquartile range])** | 7.3 [5.2–11.7]                                      | 7.3 [4.4–11.8]                    | 0.900   |
| **Attacks during past 2 years at baseline (N[ %])** |                                                      |                                   | 0.691   |
| ≤ 1                                  | 17 [65]                                              | 37 [70]                           |         |
| > 1                                  | 9 [35]                                               | 16 [30]                           |         |
| **Time since last attack at baseline (months: median [interquartile range])** | 7.4 [4.6–11.3]                                      | 7.5 [5.0–10.4]                    | 0.983   |
| **Treatment (N[ %])**                |                                                      |                                   | 0.455   |
| Placebo                              | 9 [35]                                               | 23 [43]                           |         |
| Vitamin D3                           | 17 [65]                                              | 30 [57]                           |         |
| **MRI activity after 48 weeks follow-up (N[ %])** |                                                      |                                   | 0.851   |
| No MRI activity                      | 19 [76]                                              | 37 [74]                           |         |
| MRI activity                         | 6 [24]                                               | 13 [26]                           |         |

P-value is based on Mann-Whitney U test for continuous data and Chi square test for dichotomous data.

* MRI data after 48 weeks follow-up were available for N = 25 participants from the genetic material group and N = 50 participants from the total SOLARIUM group.
3.2 Vitamin D binding protein SNP rs7041 shows increased serological response to supplementation

DBP is a known important determinant of 25(OH)D status [30]. Two missense SNPs in the DBP gene, rs4588 and rs7041, were imputed and 25(OH)D levels were compared between carriers and non-carriers of the allele associated with lower 25(OH)D levels. Baseline 25(OH)D levels did not significantly differ between the two groups (Fig 2A). However, after 48 weeks of high-dose vitamin D₃ supplementation, carriers of the rs7041 risk allele showed a lower serological response compared to non-carriers [median(IQR): 224.2 nmol/L (150.1–308.9) and 332.0 nmol/L (329.9–357.7), respectively, p = 0.013] (Fig 2B). Accordingly, carriers of the rs7041 risk allele showed a reduced absolute increase of 25(OH)D compared to non-carriers [median(IQR): 148.9 nmol/L (44.6–208.2) and 245.3 nmol/L (226.5–265.3), respectively, p = 0.020].

3.3 CYP27B1-related SNP rs12368653 associated with higher vitamin D level after supplementation

Then, two known MS risk alleles that are related to vitamin D metabolism, rs12368653 (near CYP27B1) and rs2248359 (near CYP24A1) [7], were analysed for differences in 25(OH)D levels. Again, baseline 25(OH)D values did not significantly differ between carriers and non-carriers of risk alleles (Fig 3A). After 48 weeks of supplementation, carriers of the rs12368653 risk allele showed higher levels of 25(OH)D compared to non-carriers [median(IQR): 304.1 nmol/L (251.2–336.7) and 152.0 nmol/L (140.6–158.9), respectively, p = 0.014] (Fig 3B). Additionally, carriers showed a higher absolute increase in 25(OH)D levels over 48 weeks compared to non-carriers [median(IQR): 211.0 nmol/L (170.0–261.5) and 11.2 nmol/L (5.5–77.9), respectively].

![Fig 3. Differences in 25(OH)D levels between carriers and non-carriers of CYP related MS risk alleles.](https://doi.org/10.1371/journal.pone.0261097.g003)
respectively, \( p = 0.023 \). 25(OH)D levels did not significantly differ between carriers and non-carriers of the rs2248359 risk allele.

4. Discussion

We explored the effect of vitamin D-related genetics on serological response to high-dose vitamin D\(_3\) supplementation in a cohort of relapsing-remitting MS patients treated with interferon-\(\beta\)-1a. We report an association between two genetic markers and serological response to high-dose vitamin D\(_3\) supplementation, where the DBP-linked rs7041 risk allele shows a decreased serological response, and the CYP27B1-linked rs12368653 risk allele shows an increased response in circulating 25(OH)D levels.

Studies investigating the DBP rs7041 risk allele and 25(OH)D status show varying results. A study by Sollid et al. [30] showed a difference in 25(OH)D at baseline, but not after supplementation. By contrast, a recent study by Al-Daghri et al. [27] showed no difference in 25(OH)D levels at baseline between rs7041 genotypes, but did show a decreased serological response to 6 months of vitamin D\(_3\) supplementation for carriers of the risk allele. Our findings add to the latter observation, showing a relevant effect of genetic background on serological response to vitamin D supplements.

CYP27B1 (1\(\alpha\)-hydroxylase) catalyses the hydroxylation of the inactive 25(OH)D to the active 1,25(OH)\(_2\)D. The identification of the rs12368653 risk-SNP for MS further supports the role of vitamin D in developing MS. Our findings showed an increased serological response to vitamin D\(_3\) supplementation in carriers of the risk allele. We speculate that this finding may reflect a more strict regulation of vitamin D metabolism in carriers of the CYP27B1-linked risk-allele. At present, no experimental data addressing the functional effects of this SNP on 1\(\alpha\)-hydroxylation of vitamin D have been published. These findings appear contradictory with the findings from Bhargava et al. that MS is related to a decreased response to supplementation. One explanation for this may lie in the fact that the rs12368653 risk allele shows an odds ratio for developing MS of 1.1 [7]. As such, the contribution of rs12368653 to the development of MS is very limited. Additionally, our findings are found in supra-physiological conditions and thus differ from the conditions in which MS develops. Nevertheless, differing alleles in rs12368653 appear to influence vitamin D metabolism in a biologically relevant manner, reducing the serological response to supplementation in the SOLARIUM study. As such, rs12368653 may be a relevant confounder in supplementation studies.

In our study, we find no difference in 25(OH)D levels before and after supplementation between carriers and non-carriers of both the rs4588 and rs2248359 risk alleles. However, both have been associated with 25(OH)D levels in other studies, with the rs4588 risk allele showing a decreased serological response to vitamin D\(_3\) supplementation [27], and the rs2248359 risk allele showing a decreased baseline level of 25(OH)D [31]. This discrepancy may be explained by our relatively small sample size, which increases the risk of type 2 errors.

Our findings suggest that genetic components have influenced the serological response to vitamin D\(_3\) supplementation in the SOLARIUM study and may be a relevant confounder in general supplementation studies. However, it is currently unknown how this translates to clinical outcome in MS patients. As lower 25(OH)D levels have been linked to an increased risk of disease activity [6], a relation between the serological effect of genetics and clinical outcome could be hypothesised. Additionally, findings by Graves et al. [16] show that children with an unfavourable genetic composition regarding vitamin D metabolism show an increased risk for relapses, which points towards a relevant relation between vitamin D genetics and clinical outcome in MS. Alternatively, genetic background could also influence the occurrence of adverse events of high-dose vitamin D\(_3\) supplementation, such as hypercalcaemia. Although
hypercalcaemia could negatively affect the disease course of MS [32], hypercalcaemia has not been observed in high-dose vitamin D₃ supplementation studies thus far [33]. Taken together, the influence of genetics on the clinical response to vitamin D₃ supplementation should be investigated further. It is also important to mention that our findings show an effect on supra-physiological levels of 25(OH)D after high-dose vitamin D₃ supplementation. It remains to be determined whether the reported influences of rs7041 and rs12368653 remain relevant with more physiological levels of vitamin D₃ supplementation.

Strengths of our study include its double blind nature [18]. This study is limited by its relatively small sample size, which also made it impossible to analyse each SNP separately, and instead having to use a dichotomous carrier/non-carrier designation for risk alleles.

In conclusion, the vitamin D-related genetic background influences the serological response to high-dose vitamin D₃ supplementation and, as such, may need to be corrected for in later supplementation studies. The clinical consequence of this altered serological response should be investigated further.

Supporting information
S1 Table. Baseline characteristics, genetic composition and vitamin D levels of all SOLAR-IUM participants.
(XLSX)

Acknowledgments
We would like to thank Ward de Witte for his expertise and assistance in genotyping and imputation.

Author Contributions
Conceptualization: Raymond Hupperts, Jan Damoiseaux, Joost Smolders.
Data curation: Max Mimpen, Linda Rolf, Geert Poelmans, Jody van den Ouweland, Raymond Hupperts.
Formal analysis: Max Mimpen, Jan Damoiseaux, Joost Smolders.
Funding acquisition: Raymond Hupperts, Joost Smolders.
Investigation: Max Mimpen, Jan Damoiseaux.
Methodology: Max Mimpen, Linda Rolf, Geert Poelmans, Jody van den Ouweland, Raymond Hupperts.
Project administration: Raymond Hupperts, Jan Damoiseaux, Joost Smolders.
Resources: Linda Rolf, Geert Poelmans, Jody van den Ouweland, Raymond Hupperts.
Supervision: Raymond Hupperts, Jan Damoiseaux, Joost Smolders.
Validation: Jody van den Ouweland.
Visualization: Max Mimpen.
Writing – original draft: Max Mimpen, Jan Damoiseaux, Joost Smolders.
Writing – review & editing: Linda Rolf, Geert Poelmans, Jody van den Ouweland, Raymond Hupperts.
References

1. Munger K.L., et al., Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. JAMA Neurol, 2016. 73(5): p. 515–9. https://doi.org/10.1001/jamaneurol.2015.4800 PMID: 26953778

2. Munger K.L., et al., Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA, 2006. 296(23): p. 2832–8. https://doi.org/10.1001/jama.296.23.2832 PMID: 17179460

3. Nielsen N.M., et al., Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study. Neurology, 2017. 88(1): p. 44–51. https://doi.org/10.1212/WNL.0000000000003454 PMID: 27903815

4. Ascherio A., et al., Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol, 2014. 71(3): p. 306–14. https://doi.org/10.1001/jamaneurrol.2013.5993 PMID: 24445558

5. Fitzgerald K.C., et al., Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol, 2015. 72(12): p. 1458–65. https://doi.org/10.1001/jamaneurrol.2015.2742 PMID: 26458124

6. Runia T.F., et al., Lower serum vitamin D levels are associated with a higher relapse risk in multiple sclerosis. Neurology, 2012. 79(3): p. 261–6. https://doi.org/10.1212/WNL.0b013e31825fdec7 PMID: 22700811

7. International Multiple Sclerosis Genetics, C., et al., Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011. 476(7359): p. 214–9. https://doi.org/10.1038/nature10251 PMID: 21833088

8. Rhead B., et al., Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk. Neurol Genet, 2016. 2(5): p. e97. https://doi.org/10.1212/NXG.0000000000000097 PMID: 27652346

9. Kampman M.T., et al., Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler, 2012. 18(8): p. 1144–51. https://doi.org/10.1177/1352458511434607 PMID: 22354743

10. Stein M.S., et al., A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology, 2011. 77(17): p. 1611–8. https://doi.org/10.1212/WNL.0b013e3182343274 PMID: 22025459

11. Achiron A., et al., Effect of Alfacalcidol on multiple sclerosis-related fatigue: A randomized, double-blind placebo-controlled study. Mult Scler, 2015. 21(6): p. 767–75. https://doi.org/10.1177/1352458514554053 PMID: 25344375

12. Camu W., et al., Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurol Neuroimmunol Neuroinflamm, 2019. 6(5).

13. Hupperts R., et al., Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon beta-1a. Neurology, 2019. 93(20): p. e1906–e1916. https://doi.org/10.1212/WNL.0000000000004445 PMID: 31594857

14. Soili-Hanninen M., et al., A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry, 2012. 83(5): p. 565–71. https://doi.org/10.1136/jnnp-2011-301876 PMID: 22362918

15. Bhargava P., et al., Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls. Mult Scler, 2016. 22(6): p. 753–60. https://doi.org/10.1177/1352458515600248 PMID: 26286698

16. Graves J.S., et al., Vitamin D genes influence MS relapses in children. Mult Scler, 2020. 26(8): p. 894–901. https://doi.org/10.1177/1352458519846842 PMID: 31081484

17. Muris A.H., et al., Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. J Neuroimmunol, 2016. 300: p. 47–56. https://doi.org/10.1016/j.jneuroim.2016.09.018 PMID: 27890875

18. Smolders J., et al., Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci, 2011. 311(1–2): p. 44–9. https://doi.org/10.1016/j.jns.2011.04.013 PMID: 21620416

19. Rolf L., et al., Correlation of different cellular assays to analyze T cell-related cytokine profiles in vitamin D3-supplemented patients with multiple sclerosis. Mol Immunol, 2019. 105: p. 198–204. https://doi.org/10.1016/j.molimm.2018.12.001 PMID: 30550982

20. van den Ouweland J.M., Beijers A.M., and van Daal H., Overestimation of 25-hydroxyvitamin D3 by increased ionisation efficiency of 3-epi-25-hydroxyvitamin D3 in LC-MS/MS methods not separating
both metabolites as determined by an LC-MS/MS method for separate quantification of 25-hydroxyvitamin D3, 3-epi-25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum. J Chromatogr B Analyt Technol Biomed Life Sci, 2014. 967: p. 195–202. https://doi.org/10.1016/j.jchromb.2014.07.021 PMID: 25125396

21. Smolders J., et al., Vitamin D3 supplementation and neurofilament light chain in multiple sclerosis. Acta Neurol Scand, 2020. 141(1): p. 77–80. https://doi.org/10.1111/ane.13185 PMID: 31657006

22. Ahn J., et al., Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010. 19(13): p. 2739–45. https://doi.org/10.1093/hmg/ddq155 PMID: 20418485

23. Engelman C.D., et al., Genetic and environmental determinants of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels in Hispanic and African Americans. J Clin Endocrinol Metab, 2008. 93(9): p. 3381–8. https://doi.org/10.1210/jc.2007-2702 PMID: 18593774

24. O’Brien K.M., et al., Genome-Wide Association Study of Serum 25-Hydroxyvitamin D in US Women. Front Genet, 2018. 9: p. 67. https://doi.org/10.3389/fgene.2018.00067 PMID: 29545823

25. Jiang X., et al., Genome-wide association study in 79,366 European-ancestry individuals informs the genetic architecture of 25-hydroxyvitamin D levels. Nat Commun, 2018. 9(1): p. 260. https://doi.org/10.1038/s41598-017-09736-4 PMID: 29340810

26. Wang T.J., et al., Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet, 2010. 376(9736): p. 180–8. https://doi.org/10.1016/S0140-6736(10)60588-0 PMID: 20541252

27. Al-Daghri N.M., et al., Efficacy of vitamin D supplementation according to vitamin D-binding protein polymorphisms. Nutrition, 2019. 63–64: p. 148–154. https://doi.org/10.1016/j.nut.2019.02.003 PMID: 30959383

28. Enlund-Cerullo M., et al., Genetic Variation of the Vitamin D Binding Protein Affects Vitamin D Status and Response to Supplementation in Infants. J Clin Endocrinol Metab, 2019. 104(11): p. 5483–5498. https://doi.org/10.1210/jc.2019-00630 PMID: 31365099

29. Ganz A.B., et al., Vitamin D binding protein rs7041 genotype alters vitamin D metabolism in pregnant women. FASEB J, 2018. 32(4): p. 2012–2020. https://doi.org/10.1096/fj.201700992R PMID: 29196501

30. Sollid S.T., et al., Effects of vitamin D binding protein phenotypes and vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D. Eur J Endocrinol, 2016. 174(4): p. 445–52. https://doi.org/10.1530/EJE-15-1089 PMID: 26733479

31. Perez-Perez S., et al., Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. Eur J Neurol, 2018. 25(12): p. 1446–1453. https://doi.org/10.1111/ene.13749 PMID: 29996002

32. Hausler D., et al., High dose vitamin D exacerbates central nervous system autoimmunity by raising T-cell excitatory calcium. Brain, 2019. 142(9): p. 2737–2755. https://doi.org/10.1093/brain/awz190 PMID: 31302671

33. Smolders J., Damoiseaux J., and Hupperts R., Hypercalcaemia rather than high dose vitamin D3 supplements could exacerbate multiple sclerosis. Brain, 2019. 142(12): p. e71. https://doi.org/10.1093/brain/awz339 PMID: 31665228